PDS Planning Inc Purchases 2,541 Shares of AbbVie Inc. $ABBV

PDS Planning Inc boosted its position in AbbVie Inc. (NYSE:ABBV) by 2.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 110,533 shares of the company’s stock after acquiring an additional 2,541 shares during the quarter. AbbVie accounts for 1.7% of PDS Planning Inc’s holdings, making the stock its 16th largest holding. PDS Planning Inc’s holdings in AbbVie were worth $25,256,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. Ellenbecker Investment Group grew its stake in shares of AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA grew its stake in shares of AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC grew its stake in shares of AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC grew its stake in shares of AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after buying an additional 45 shares during the last quarter. Finally, Willner & Heller LLC grew its stake in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after buying an additional 46 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Motley Fool says ABBV is a “no‑brainer” buy on dips, highlighting its high dividend, cash flow and defensive pharma profile as reasons value/dividend investors should buy weakness. Why AbbVie Is a No-Brainer Stock to Buy on the Dip
• Positive Sentiment: AbbVie announced head‑to‑head Phase 4 psoriasis study updates — a potential near‑term clinical catalyst that could influence commercial positioning in immunology if results favor AbbVie’s therapy. AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors
• Positive Sentiment: AbbVie kicked off a Phase 1 trial for ABBV‑295 (obesity), signalling a strategic push into the high‑growth weight‑loss market where success could materially expand future revenue streams. AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial
• Positive Sentiment: AbbVie paid an upfront of ~$650M to RemeGen for global rights to RC148 — a sizeable bolt‑on that strengthens the company’s oncology/rare disease pipeline (near‑term cash outflow but potential long‑term value). RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
• Neutral Sentiment: Evercore ISI trimmed its price target slightly ($233→$232) but kept an Outperform rating — a minor analyst tweak that maintains institutional conviction. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally
• Neutral Sentiment: Sector pieces and market reports (value stock roundups; thyroid‑eye‑disease market research) include AbbVie as a key player — these reinforce investor awareness but don’t move fundamentals immediately. 1 Value Stock Worth Your Attention and 2 That Underwhelm Thyroid Eye Disease Treatment Market Research Report 2026
• Negative Sentiment: Technicals are a headwind: the stock is trading below both the 50‑day and 200‑day moving averages, which can pressure short‑term sentiment and limit upside until price recovers those levels.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several analyst reports. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. Piper Sandler boosted their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Finally, Evercore reduced their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

AbbVie Stock Up 0.3%

ABBV stock opened at $209.00 on Friday. The firm has a market cap of $369.55 billion, a price-to-earnings ratio of 88.56, a PEG ratio of 0.74 and a beta of 0.38. AbbVie Inc. has a 12-month low of $168.54 and a 12-month high of $244.81. The company’s fifty day simple moving average is $219.30 and its 200 day simple moving average is $223.67.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.